Cancer Non-Governmental Organisations (CANGO)

A meeting of Cancer Non-Governmental Organisations (CANGO) was hosted by CANGO, chairman; Peter Fergusson (CEO of Leukaemia & Blood Cancer NZ) on Monday 1st August 2022 (in person and online). Lung Foundation New Zealand is an active member of CANGO. Members collaborate on key issues facing the sector and through advocacy to improve the cancer […]

World Lung Cancer Day, 1st August 2022

Lung Foundation New Zealand observed World Lung Cancer Day to honour and unite all kiwis that have been affected by New Zealand’s Biggest Cancer Killer. The purpose of World Lung Cancer Day is to raise awareness about lung cancer and its global impact, to inform and educate an understanding of lung cancer risks and the […]

Pharmac issue RFP for immunotherapy

We are pleased to finally see a RFP for lung cancer immunotherapy issued. When immunotherapy treatment is funded for stage four lung cancer (NSCLC), it will be life changing for approximately 26 patients every week.. The combined voice of; patients, carers, patients family’s, health care professionals, specialists, researchers, advocates and community has made this possible. […]

Lung Foundation at the NZ Lung Cancer Conference

Lung Foundation New Zealand representatives; Chief Executive, Philip Hope and Assoc Prof of Oncology, Chris Atkinson attended and presented at the NZ Lung Cancer Conference. 2022 July – NZ Lung Cancer Conference Click to view the conference programme. https://az659834.vo.msecnd.net/eventsairseasiaprod/production-outshine-public/0fa313da4ba547a5a8d74d4cdb36241e  

Lung Foundation NZ’s response to Budget 2022

Lung Foundation New Zealand Tuapapa Pukahukahu Aotearoa understands there are many pressures on government (Pharmac too), especially in 2022. We acknowledge and support the philosophy the government has employed with its response to covid and reducing the impacts of covid, which is informed by scientific evidence and well-being; dedicated to reducing the burden on the […]

Analysis of Cancer Medicine Availability in Aotearoa by Te Aho o Te Kahu

While we acknowledge Te Aho o Te Kahu for publishing this report, it is merely telling us what we already know. Notable is the timing of this report which well follows the review of Pharmac (and prior to that the flawed health system review..). Till now Te Aho o Te Kahu hasn’t acknowledged the huge […]

Lung Foundation NZ acknowledges decision to fund durvalumab

Pharmac’s decision to fund immunotherapy treatment durvalumab (imfinzi) for stage 3 lung cancer is a small step forward. Lung Foundation New Zealand (LFNZ) acknowledges the leaders and clinical advisors at Pharmac and the key people at AstraZeneca for getting durvalumab (imfinzi) across the line. This funding decision also highlights extreme inequities with access to treatments […]

Respiratory Research Review Features Lung Cancer

Lung Foundation New Zealand (LFNZ) really values the collaboration our cause has with Research Review. We’re pleased to publish the latest issue of Respiratory Research Review which focuses on Lung Cancer. Respiratory_Research_Review_Issue_193_Lung_Cancer

New research to focus on inequity in lung cancer

While, Lung Foundation New Zealand (LFNZ) endorses the funding decision and we applaud the efforts of the researchers that dedicate their life to improving health policy, providing lung cancer patients access to more treatment options NOW, will prevent premature death and eliminate inequities.   https://www.rnz.co.nz/news/national/459893/new-research-fund-to-focus-on-inequity-in-lung-cancer-treatment-diagnosis